Jazz Pharmaceuticals (JAZZ) Highlights Growth at Goldman Sachs Healthcare Conference

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) is one of the 7 most undervalued pot stocks to buy according to analysts. On June 11, the company presented at the Goldman Sachs 46th Annual Global Healthcare Conference, where it outlined its strategic growth initiatives and acknowledged various challenges.

Jazz Pharmaceuticals (JAZZ) Highlights Growth at Goldman Sachs Healthcare Conference

A close up of cannabis plants growing in an outdoor facility, symbolizing the product of the cannabinoid company.

According to the presentation, Jazz Pharmaceuticals reported robust growth in its neuroscience segment, particularly with Xywav (for sleep disorders like narcolepsy and idiopathic hypersomnia) and Epidiolex (for epilepsy). These products showed “strong growth” in the first quarter of 2025. Xywav’s low sodium content and flexible dosing were highlighted as key market advantages.

The company detailed that it is expanding its oncology portfolio and pipeline, which now accounts for over half of its 2024 revenue, up from 26% in 2018. Key oncology initiatives include Zanidatamab (Ziihera), Zepzelca (lurbinectedin), Subzelca (formerly JZP-351), and Dordavapril (from Chimerix acquisition).

The company stated that beyond marketed products, it is advancing its pipeline with upcoming product launches and regulatory decisions anticipated to drive future growth. This includes the orexin program (JZP-441 trials being monitored for cardiovascular effects) and prasinezumab in Europe.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) expanded its footprint into the cannabis sector with the acquisition of GW Pharmaceuticals. Consequently, it develops and markets FDA-approved drugs that contain purified cannabis-based substances, specifically cannabidiol (CBD), to treat serious illnesses.

While we acknowledge the potential of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than JAZZ and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 15 Successful Spin-Off Companies and Their 2025 Returns and 12 Best Consumer Goods Stocks Billionaires Are Quietly Buying.

Disclosure: None. This article is originally published at Insider Monkey.